TEVA

Analysis of Teva share price

BUY   SELL
72% of retail investor accounts lose money when trading CFDs with this provider.
 
Chart provided by Tradingview

Are you interested in the share of the Israeli group Teva and do you want to invest on its price? We propose to you, through this article entirely devoted to this value, to discover which are the elements which you will be able to use within the framework of your analyses of its price. We are going to take a closer look at the activities of this Israeli company and its various products on the market. We will also discover together the direct competitors of this group in the world. We will also give you some examples of recent partnerships of this company and finally, we will help you to realize its fundamental analysis.

Elements that can influence the price of this asset:

Analysis N°1

The group's acquisitions and the purchase of new subsidiaries are of course major events for Teva's growth and must be closely monitored.

Analysis N°2

We will also keep an eye on the evolution of the generic drug market worldwide, a segment in which Teva is very present.

Analysis N°3

The expiration of patents on many drugs that allow their use by Teva is an important factor that can sometimes boost this stock.

Analysis N°4

Of course, changes in the regulations and rules for marketing drugs will also have to be taken into account.

Analysis N°5

We will also be watching closely the growing competition in the generic sector with the arrival of new major players who could take market share from Teva.

72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500

General presentation of Teva

Now we're going to give you a chance to learn more about Teva by exploring its core business and learning about its biggest sources of revenue.

Teva Pharmaceutical Industries is an Israeli pharmaceutical company. It is also a leader in the development, production and sale of generic pharmaceutical products.

To better understand the Teva Group's activities, they can be divided into different segments according to the share of sales they generate and in this way:

  • Generic drugs account for 51.6% of the group's sales, with drugs for the treatment of multiple sclerosis, Parkinson's disease and immune disorders.
  • Branded products account for 35.4% of the company's sales, with treatments for central nervous system disorders accounting for 67.9%, respiratory diseases for 13.5%, urogenital and hormonal disorders for 6.7%, cancers and immune disorders for 4.1%, and other diseases such as infections, muscular and orthopaedic problems.
  • Organic fine chemicals represent 4.1% of the turnover with active ingredients for the production of medicines.
  • Finally, the remaining 8.9% of the company's turnover comes from other types of products including OTC products.

As regards the geographical distribution of the group's activities, 48.1% of its sales are generated in the USA, 30.9% in Europe and 21% in the rest of the world.

Analysis of Teva share price
72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500

The major competitors of Teva

Let's explore the Teva Pharmaceuticals Group's competitive environment with a look at the company's various competitors that you should watch out for in your analysis of this stock:

Abbott 

The Abbott Laboratories group is an American company that has been in existence since 1988 and is based in Chicago. It employs more than 90,000 people worldwide. The company specializes in generic drugs and other health care products.

Merck 

The Merck group is another direct competitor of Teva Pharmaceuticals. This German company, founded in 1668, specializes in the pharmaceutical sector as well as in the chemical sector.

Bayer 

Finally, we will also follow the German group Bayer AG which is a major pharmaceutical and agrochemical company. The group develops medicines, including generic drugs, but also over-the-counter health products, veterinary products and agrochemicals and sanitary products for the agricultural sector since its acquisition of Monsanto.


The major partners of Teva

Let's take a look at some of the Teva Pharmaceuticals group's allies with two examples of recent partnerships that the company has established:

Takeda

The first partnership we're going to talk about is the one that Teva has set up with the Japanese laboratory Takeda in Japan. The two companies have thus created a joint venture owned 51% by Teva and 49% by Takeda and whose objective is to support the growth of the generic drug market in Japan. Effectively launched in 2016, the venture offers high-quality generic medicines from Teva and some older products from Takeda to patients and healthcare professionals in the country through Takeda's distribution network and Teva's diversified product portfolio.

Procter & Gamble 

In another partnership, formed in 2011, Teva and the Procter & Gamble Group formed a joint venture in the consumer healthcare sector. The new entity, called PGT Healthcare, is based in Switzerland and operates in most markets outside North America. The partnership has also enabled both companies to develop new brands for the North American market.

72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500

Frequently Asked Questions

What markets are Teva Pharmaceuticals shares listed on?

Teva Pharmaceuticals shares are currently listed on two different financial markets. The stock is primarily listed on the NYSE American market in the Nasdaq Global Select Market section, but since the company is headquartered in Israel, it is also listed on the Tel Aviv stock market.

What were Teva's latest financial results?

Of course, it is essential to know the recent financial releases of Teva Pharmaceuticals Group before taking a position on this stock. At present, the group's latest annual results are for fiscal 2019 with sales of $16,887 million and net income of $999 million in 2019 in loss.

Who are the main shareholders of Teva today?

The capital of the Teva Pharmaceuticals group is divided between floating shares and some major shareholders. These main shareholders are in particular the Berkshire Hataway group, the Wellington Management Company and the American investment fund BlackRock. Of course, this shareholding structure is likely to change over time with the acquisition of new holdings or the sale of shares on the market in order to raise funds.

72% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. This is an advert for trading CFDs on Plus500